Brain-Training Firm, FTC Settle

San Francisco-based Lumos Labs, creator of the brain-training program Lumosity, will pay $2 million to settle deceptive-advertising charges raised by the US Federal Trade Commission.

Written byTracy Vence
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

PEXELSThe company behind the popular brain-training program Lumosity will pay the US Federal Trade Commission (FTC) $2 million in a settlement related to deceptive advertising charges, the agency announced yesterday (January 5). As part of the settlement, San Francisco-based Lumos Labs is to notify Lumosity customers of the FTC action and provide instructions to cancel auto-renewal billing. (The program is available for purchase through monthly or lifetime subscriptions.)

“Lumosity preyed on consumers’ fears about age-related cognitive decline, suggesting their games could stave off memory loss, dementia, and even Alzheimer’s disease,” Jessica Rich, director of the FTC’s Bureau of Consumer Protection, said in the statement. “But Lumosity simply did not have the science to back up its ads.” (See “Opinion: Can the Brain Be Trained?”)

In a statement sent to reporters (via Reuters), Lumos Labs said the FTC charges were tied to “marketing language that has been discontinued.” STAT News reported that the company said its focus “will not change.”

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies